A Phase 2 Study of LY573636-Sodium [tasisulam] Administered as Second-Line or Third-Line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma.

Trial Profile

A Phase 2 Study of LY573636-Sodium [tasisulam] Administered as Second-Line or Third-Line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Tasisulam (Primary)
  • Indications Sarcoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Last checked against M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top